Selectivity and Interference Studies in Forensic LC-MS/MS

Selectivity asks whether an analytical method can distinguish the target analyte from everything else that may produce a similar signal. In forensic LC-MS/MS, that question is broader than whether a chromatographic peak appears at approximately the expected retention time. A defensible method must consider endogenous matrix components, other drugs and metabolites, isotope-labeled internal standards, isomers and isobars, in-source fragments, carryover, and concentration-dependent effects that can create or distort a reported signal.

This is why interference testing belongs both to method validation and to case-specific review. A method may have passed its original validation and still encounter a newly marketed drug, unusual metabolite, extreme concentration, or specimen matrix that was not represented in the original challenge set.

What is selectivity in forensic toxicology?

Selectivity is the ability of a method to identify or measure an analyte in the presence of other substances expected in the specimen. In practical forensic work, selectivity is demonstrated by challenging the method with relevant blank matrices, target compounds, common co-occurring drugs, metabolites, internal standards, and structurally or mass-spectrometrically similar compounds.

ANSI/ASB Standard 036 establishes minimum practices for forensic toxicology method validation and requires laboratories to demonstrate that methods are fit for their intended use. Modern LC-MS/MS and LC-QTOF validation studies routinely include dedicated selectivity and interference experiments as part of that framework.

Selectivity is not the same as sensitivity

A highly sensitive method can detect very small signals, but that does not automatically make those signals specific to the target analyte. Sensitivity concerns how little analyte can be detected or measured. Selectivity concerns whether the observed response can be attributed to the intended analyte rather than something else.

This distinction matters most near reporting limits, where a small interfering contribution can represent a substantial portion of the total observed signal. See Reporting Limits in Forensic Toxicology.

Major sources of analytical interference

Potential interference	How it can affect a result	What review should examine
Endogenous matrix compounds	May suppress, enhance, or overlap with the analyte signal	Blank matrix sources, chromatograms, matrix-effect studies, retention behavior
Other drugs or metabolites	May share transitions, masses, fragments, or retention regions	Interference challenge list, authentic-case experience, alternate transitions
Isomers and isobars	Can have the same nominal or exact mass and similar fragments	Chromatographic resolution, reference standards, reporting convention
Internal standards	Impurities, isotopic overlap, or high concentration can contribute signal	Internal-standard-only injections, isotope purity, transition design
In-source fragments	A different compound may fragment before mass selection and mimic the target	Precursor/product relationships, chromatographic profile, alternate conditions
Carryover	Residual analyte from a prior injection can appear in a later specimen	Injection sequence, blanks after high positives, autosampler wash performance
Extreme concentrations	High-abundance compounds can create cross-talk, saturation, or unexpected fragments	High-concentration challenge data, dilution results, neighboring transitions

How laboratories evaluate blank-matrix interference

One common validation approach is to analyze multiple independent blank specimens from the intended matrix and determine whether any signal appears at the analyte or internal-standard retention time. Using multiple donors matters because blood and urine are chemically heterogeneous. A single blank specimen cannot represent the variability expected across casework.

A recent broad LC-QTOF validation for 946 drugs and metabolites evaluated authentic antemortem and postmortem blood and urine sources, target analytes, and isotope-based internal standards when assessing interferences and selectivity. The study also documented groups of compounds that could not be completely distinguished by retention time or library criteria alone. See Sarkisian and Rodda, Journal of Analytical Toxicology.

Drug-to-drug and metabolite interference testing

Forensic specimens rarely contain only one compound. Validation therefore should challenge the method with other drugs reasonably expected in the laboratory’s case population. The most informative challenges include compounds with similar masses, common fragments, close retention times, structurally related metabolites, and very high therapeutic or toxic concentrations.

A modern 57-analyte LC-MS/MS method reported evaluating 127 other drugs and 82 deuterated internal standards for interference. Closely related compounds that could not be chromatographically separated were explicitly grouped rather than over-interpreted as individually resolved analytes. See Multi-class analysis of 57 drugs by LC-MS/MS.

Why isomers and isobars deserve special attention

Compounds can share the same nominal mass, the same exact mass, or highly similar product-ion patterns. In those situations, mass spectrometry alone may not provide sufficient discrimination. Chromatographic separation, alternative transitions, ion ratios, spectral libraries, reference standards, or an explicit grouped-reporting convention may be required.

This issue has become more important as forensic laboratories expand panels to include large numbers of novel psychoactive substances. A validated synthetic-opioid method, for example, specifically evaluated isobaric fentanyl-related compounds and relied on retention time and ion-ratio behavior to distinguish closely related targets. See Analysis of novel synthetic opioids and xylazine by LC-MS/MS.

For the related identification framework, see LC-MS/MS Identification Criteria in Forensic Toxicology.

Interferences can emerge after a method is validated

Validation is necessarily based on the compounds and specimen sources known and available at the time. It cannot guarantee that no future drug, metabolite, supplement, or analytical artifact will interfere.

A useful real-world example involved norbuprenorphine confirmation testing. Multiple laboratories observed interference near the norbuprenorphine retention time and ultimately linked it to quetiapine metabolites. The affected transitions could not be reported reliably until interference-free transitions were identified. See Norbuprenorphine Interferences from Quetiapine Metabolites.

Another published investigation documented a false-positive LC-QTOF identification of 4-MePPP caused by an in-source fragment of a tramadol metabolite. The interference satisfied the initial identification criteria until the laboratory investigated the recurring association with tramadol and confirmed the source experimentally. See Investigation and Resolution of Interference in the LC-QTOF-MS Detection of 4-MePPP.

Internal standards can also create or reveal problems

Stable-isotope internal standards are valuable normalization tools, but they should also be evaluated as potential sources of analytical contribution. Laboratories commonly test whether the internal standard contains unlabeled analyte, whether its isotope distribution overlaps the target transition, and whether the chosen concentration creates cross-talk or detector effects.

A normal internal-standard response does not prove that the analyte signal is interference-free. Conversely, an abnormal internal-standard response can be a useful warning that the specimen behaved differently from calibrators and controls. See Stable-Isotope Internal Standards in Forensic LC-MS/MS.

Interference versus matrix effect

These concepts overlap but are not identical. A matrix effect changes ionization efficiency and can suppress or enhance the analyte response without necessarily creating a false analyte peak. An interference may create, distort, or overlap the analytical signal itself. Both can coexist.

Case review should therefore examine both the selectivity/interference validation and the matrix-effect validation. See How Matrix Effects Are Evaluated in LC-MS/MS Forensic Toxicology.

What should a case reviewer request?

the laboratory’s current and historical method validation reports;
the specific selectivity and interference experiments performed;
the list and concentrations of drugs, metabolites, matrices, and internal standards challenged;
blank-matrix chromatograms and the number of independent matrix sources;
target and qualifier transitions, ion-ratio criteria, and retention-time criteria;
chromatograms for the questioned specimen, calibrators, controls, and adjacent injections;
any documented unresolved isomers, isobars, grouped analytes, or known interferences;
records of method changes triggered by newly discovered interferences;
repeat analysis, alternative transitions, dilution, or confirmation using another method when performed.

Does passing validation prove there was no interference in this case?

No. Validation demonstrates performance under the conditions that were actually tested. It does not prove that every possible future compound, metabolite, specimen condition, or concentration has been excluded. A case-specific interference concern becomes stronger when the questioned signal shows abnormal retention, ion ratios, peak shape, concentration dependence, co-occurring compounds, or inconsistent repeat behavior.

Does a matching retention time prove identity?

No. Retention time is one identification feature. Confirmatory interpretation may also depend on precursor/product-ion behavior, ion ratios, spectral comparison, resolution from known interferences, and the laboratory’s validated identification criteria. See Ion-Ratio Failures and Borderline Confirmatory Results.

Can an interference inflate a quantitative result without creating a false positive?

Yes. A co-eluting compound may add response to one or more monitored transitions or distort integration while the target analyte is genuinely present. In that situation the issue is not necessarily whether the analyte exists, but whether the reported concentration is analytically specific and unbiased.

Case-review takeaway

Selectivity is not a one-time checkbox. It is a demonstrated property of a method under defined conditions and an ongoing casework question when new compounds, unusual matrices, extreme concentrations, or atypical chromatograms appear. The strongest forensic review asks what potential interferents were actually tested, whether the questioned specimen resembles the conditions represented in validation, and whether the raw chromatographic and mass-spectrometric data support an analyte-specific interpretation.